Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Jul 7 · above the Ichimoku cloud · RSI 49 · MACD below its signal
| 41.72 | 52-week high | +185.56% |
| 19.60 | Previous month high | +34.15% |
| 18.19 | R3 (classic) | +24.48% |
| 18.00 | Previous week high | +23.20% |
| 17.27 | R2 (classic) | +18.23% |
| 16.44 | R1 (classic) | +12.50% |
| 16.36 | Previous day high | +11.98% |
| 15.52 | Pivot | +6.25% |
| 14.69 | S1 (classic) | +0.52% |
| 14.61 | Price now | |
| 14.61 | Previous day low | −0.00% |
| 14.41 | Previous week low | −1.37% |
| 13.77 | S2 (classic) | −5.73% |
| 12.94 | S3 (classic) | −11.45% |
| 9.15 | Previous month low | −37.37% |
| 6.79 | 52-week low | −53.52% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $442.3K | 0.00% | 52.84K | +49% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BNR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 25, 2026 | Han YushengDirector | Purchase at price 7.45 - 9.25 per share. | 731.4K | $6.18M |
| Mar 30, 2026 | Han YushengDirector | Purchase at price 17.36 per share. | 314.9K | $5.47M |
TimeframesDown on the hourly, mixed on the daily, weekly and monthly.
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
bouncing over the 21 EMA
over a flat 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 69.0 | -24.2 | -37.6 | 5.4 | -45.2 | -10.2 | 6.3 | 6.2 | 86.6 | -17.1 | −27.5% | ||
| 2025 | -1.0 | -5.5 | -28.7 | -35.1 | 6.2 | 1.9 | 82.3 | 50.9 | -0.5 | 55.6 | 60.4 | -6.7 | +198.5% |
| 2024 | -7.5 | -0.9 | -14.6 | 3.7 | -5.3 | -9.8 | 14.2 | -28.1 | -38.3 | -13.9 | 119.2 | 9.6 | −27.4% |
| 2023 | 29.3 | 12.0 | -13.8 | 10.7 | -16.1 | -17.6 | -16.3 | -24.7 | -28.4 | -1.6 | -13.0 | 12.0 | −58.7% |
| 2022 | -5.6 | -6.3 | 10.2 | -40.7 | -56.4 | 21.3 | 9.6 | 22.9 | -39.0 | -13.8 | 21.8 | -10.4 | −76.4% |
| 2021 | 30.6 | 19.3 | -25.2 | 13.3 | -11.2 | 8.8 | -22.7 | -18.2 | -4.0 | -21.2 | 9.7 | -38.4 | −58.7% |
| 2020 | -7.4 | -7.8 | 8.8 | 23.1 | -7.6 | -19.0 | −14.5% |
No analyst coverage for this instrument.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.